肿瘤生物相似药市场：用途（癌症药物、支持性护理药物）、最终用户（医院、零售药房）划分 - 2023-2030 年全球预测

预计2023年全球肿瘤生物相似药市场将达到46.5176亿美元，复合年增长率为18.09%，大幅成长，2030年将达到149.1629亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球肿瘤生物相似药市场至关重要。透过检验业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使用户能够根据自己的具体需求做出资讯的决策。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.肿瘤生物相似药的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球肿瘤生物相似药市场的阻碍因素和影响为何？

3.全球肿瘤生物相似药市场在预测期内应投资哪些产品/细分市场/应用/领域？

4.你们在全球肿瘤生物相似药市场的竞争策略是什么？

5.全球肿瘤生物相似药市场的技术趋势和法律规范是什么？

6.全球肿瘤生物相似药市场主要厂商的市占率为何？

7. 您认为肿瘤生物相似药进入全球市场的合适型态和策略性倡议是什么？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 产品商业化的快速法规核准
    • 各种癌症和白血病的发生率增加
    • 临床药物开发的最新创新
  • 抑制因素
    • 调查费用昂贵
  • 机会
    • 介绍新的和创新的治疗方案
    • 策略联盟投资与产能扩张
  • 任务
    • 有限的临床安全性和有效性资料
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章肿瘤生物相似药市场：依用途

• 癌症治疗药物
• 支持治疗药物

第7章肿瘤生物相似药市场：依最终用户分类

• 医院
• 零售药房

第8章美洲肿瘤生物相似药市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太肿瘤生物相似药市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲的肿瘤生物相似药市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Oncology Biosimilars Market is forecasted to grow significantly, with a projected USD 4,651.76 million in 2023 at a CAGR of 18.09% and expected to reach a staggering USD 14,916.29 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Oncology Biosimilars Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Oncology Biosimilars Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Application, market is studied across Cancer Treatment Drugs and Supportive Care Drugs. The Cancer Treatment Drugs is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals and Retail Pharmacies. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Oncology Biosimilars Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oncology Biosimilars Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Biosimilars Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Biosimilars Market?

4. What is the competitive strategic window for opportunities in the Global Oncology Biosimilars Market?

5. What are the technology trends and regulatory frameworks in the Global Oncology Biosimilars Market?

6. What is the market share of the leading vendors in the Global Oncology Biosimilars Market?

7. What modes and strategic moves are considered suitable for entering the Global Oncology Biosimilars Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Oncology Biosimilars Market, by Application, 2022 vs 2030
• 4.3. Oncology Biosimilars Market, by End-User, 2022 vs 2030
• 4.4. Oncology Biosimilars Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
    • 5.1.1.2. Rising incidence of various types of cancers and leukemia
    • 5.1.1.3. Recent innovation in clinical drug development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs involved in the research
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new and innovative treatment options
    • 5.1.3.2. Strategic alliances and investment for capacity expansion
  • 5.1.4. Challenges
    • 5.1.4.1. Limited clinical safety and efficacy data
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Oncology Biosimilars Market, by Application

• 6.1. Introduction
• 6.2. Cancer Treatment Drugs
• 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
• FIGURE 2. ONCOLOGY BIOSIMILARS MARKET SIZE, 2022 VS 2030
• FIGURE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
• FIGURE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. ONCOLOGY BIOSIMILARS MARKET DYNAMICS
• FIGURE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 13. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 22. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 97. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 98. ONCOLOGY BIOSIMILARS MARKET LICENSE & PRICING